Share Email Print

Proceedings Paper

GNR@mSiO2-TDM1 conjugates as multimodal platform for breast cancer therapy as well as enhanced photoacoustic agent
Author(s): Fei Cao; Qian Yao; Xiuhong Wang
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

The development of combination of two or more therapies to fight against cancer together has been important research in oncology. Here we rationally designed a novel nanodrug which can incorporate active targeting, antibody therapy, drug therapy and photothermal therapy within one single platform to fight against Her2-positive breast cancer. To this end, a layer of mesoporous SiO2 was encapsulated onto the gold nanorods followed by covalent association of breast cancer drug TDM1 to the silica shell. TDM1 is an antibody drug conjugate consisting of engineered antibody trastuzumab and anti-miotic agent emtansine. Drug therapy followed by photothermal therapy using NIR laser (793nm) specifically ablated Her2-positive breast cancer cells with enhanced efficiency. In addition, the engineered nanodrug has amplified photoacoustic performance allowing sensitive detection of Her2-positive cancer cells.

Paper Details

Date Published: 29 February 2016
PDF: 7 pages
Proc. SPIE 9689, Photonic Therapeutics and Diagnostics XII, 96894A (29 February 2016); doi: 10.1117/12.2212140
Show Author Affiliations
Fei Cao, Beijing Univ. of Technology (China)
Qian Yao, Beijing Univ. of Technology (China)
Xiuhong Wang, Beijing Univ. of Technology (China)

Published in SPIE Proceedings Vol. 9689:
Photonic Therapeutics and Diagnostics XII
Hyun Wook Kang; Guillermo J. Tearney M.D.; Melissa C. Skala; Bernard Choi; Andreas Mandelis; Brian J. F. Wong M.D.; Justus F. Ilgner M.D.; Nikiforos Kollias; Paul J. Campagnola; Kenton W. Gregory M.D.; Laura Marcu; Haishan Zeng, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?